Optimizing Outcomes in Ovarian and Endometrial Cancers: The Role of Antibody-Drug Conjugates

Panelists discuss how antibody-drug conjugates (ADCs) and molecular testing are reshaping treatment strategies in ovarian and endometrial cancers by enabling more personalized, targeted care, while addressing practical challenges such as tissue limitations, tumor heterogeneity, and the evolving role of liquid biopsy in optimizing diagnostic accuracy.

Panelists discuss how evolving insights into HER2 expression—drawn from parallels with breast cancer—highlight the need for standardized HER2 testing in gynecologic oncology, as emerging data on HER2-low status and variability in current testing approaches underscore both the therapeutic potential of antibody-drug conjugates (ADCs) and the challenges of implementing precision medicine in this setting.

Panelists discuss how the recent accelerated approval of trastuzumab deruxtecan (T-DXd) in HER2-expressing endometrial cancer prompts critical questions about treatment sequencing, as clinicians weigh efficacy, toxicity, and emerging evidence to personalize therapy in a rapidly evolving gynecologic oncology landscape.

Panelists discuss how the accelerated approval of trastuzumab deruxtecan (T-DXd) offers a promising new treatment option for patients with HER2-positive gynecologic cancers, while highlighting the need for confirmatory trials to refine patient selection, testing methodologies, and treatment sequencing strategies, as well as managing varying patient responses and addressing tolerability concerns.

Panelists discuss how mirvetuximab soravtansine (MIRV), an antibody-drug conjugate, has become a vital treatment for platinum-resistant ovarian cancer, highlighting its effectiveness in patients with high folate receptor alpha expression, its well-tolerated profile with manageable toxicities, and the potential for expanding its use into earlier treatment lines and combination therapies.

Panelists discuss how the rapid evolution of antibody-drug conjugates (ADCs) in gynecologic cancers, including promising agents such as mirvetuximab soravtansine and toriluzumab, is generating excitement, with a focus on optimizing treatment sequencing and exploring combinations of ADCs to improve outcomes for patients with platinum-resistant ovarian cancer.

Panelists discuss how managing interstitial lung disease (ILD) associated with antibody-drug conjugates (ADCs) such as mirvetuximab soravtansine requires proactive monitoring, including baseline and ongoing chest CT scans, early intervention with steroids, and close collaboration with pulmonologists and radiologists to minimize risks and ensure patient safety during treatment.

Panelists discuss how early detection and proactive management of ocular toxicities associated with mirvetuximab soravtansine, including regular screening, eye exams, and collaboration with ophthalmologists, are essential for ensuring timely intervention and minimizing long-term complications such as cataracts, particularly as the drug transitions to broader clinical use.

Panelists discuss how the evolving role of antibody-drug conjugates (ADCs) in treating gynecologic cancers, including ovarian, endometrial, and cervical cancers, offers exciting opportunities for more personalized treatments that could improve progression-free survival and quality of life, while addressing challenges in therapy sequencing, toxicity management, and biomarker-driven approaches.